Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001140361-25-004241
Filing Date
2025-02-13
Accepted
2025-02-13 14:20:23
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4587
2 EXHIBIT A ef20043541_ex99-1.htm EX-99.1 4550
  Complete submission text file 0001140361-25-004241.txt   10946
Mailing Address 1165 EASTLAKE AVE E SEATTLE WA 98109
Business Address 1165 EASTLAKE AVE E SEATTLE WA 98109 206-659-0067
Adaptive Biotechnologies Corp (Subject) CIK: 0001478320 (see all company filings)

EIN.: 270907024 | State of Incorp.: WA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91363 | Film No.: 25619345
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 605 THIRD AVENUE 38TH FLOOR NEW YORK NY 10158
Business Address 605 THIRD AVENUE 38TH FLOOR NEW YORK NY 10158 212-610-6100
Nikko Asset Management Americas, Inc. (Filed by) CIK: 0001480751 (see all company filings)

EIN.: 941302123 | State of Incorp.: DE | Fiscal Year End: 0310
Type: SCHEDULE 13G/A